The cutting-edge OncoPortal™ Mutation Tracker
add-on module enables precision monitoring of evolving genomic
cancer drivers
BOSTON,
MA and ROLLE, Switzerland, Jan. 28,
2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a cloud-native healthcare technology company and a global leader in
data-driven medicine, has unveiled the OncoPortal™ Mutation
Tracker — a longitudinal MRD tracking tool designed for disease
monitoring in the context of oncology. This innovation underscores
SOPHiA GENETICS' commitment to advancing data-driven approaches for
improved oncology insights.
Tracking genomic variants across multiple time points in the
same patient is becoming increasingly critical in cancer care,
particularly for identifying treatment resistance or detecting
residual cancer cells, such as in Measurable Residual Disease (MRD)
management. The integration of longitudinal tracking capabilities
with next-generation sequencing (NGS) allow the parallel detection
of cancer-specific genetic mutations at very low frequencies. This
combined approach enables early identification of residual disease
or emerging variants, providing a more precise assessment of
disease burden, better stratification of high-risk patients, and
the ability to tailor treatments to the cancer's unique genomic
profile.
The OncoPortal™ Mutation Tracker augments the SOPHiA DDM™
Platform's core analytical capabilities to allow clinical
researchers to longitudinally monitor evolving genomic variants
across multiple time points, providing a comprehensive view of
disease evolution. The OncoPortal™ Mutation Tracker enhances
workflow efficiency for longitudinal variant tracking by offering
flexible low frequency variant selection, customizable threshold
settings, and reporting features to generate longitudinal graphical
representations, simplifying the process of tracking and analyzing
genetic changes over time.
"The ability to reliably track low frequency variants
longitudinally is a game-changer because it allows the detection of
even the smallest traces of cancer that can evade traditional
methods of testing and ultimately drive relapse," said Philippe
Menu, M.D., Ph.D., Chief Medical Officer and Chief Product Officer,
SOPHiA GENETICS. "With this new
longitudinal tracking capability, we offer a highly customizable,
user-friendly solution to enable the generation of novel insights
for clinical research. Precise tracking of key genomic variants
over time has the potential to eventually enable earlier
intervention and more tailored disease management, which may lead
to better long-term outcomes for patients."
"This longitudinal interface represents the solution we've been
seeking to unite our oncologists in embracing broader adoption of
NGS. It's the missing piece that unlocks a new frontier in
personalized, data-driven medicine," said Dr. Christophe Marzac,
Head of the Hematology-Immunology Unit, Gustave Roussy
Institute.
For more information on the OncoPortal™ Mutation Tracker,
visit SOPHiAGENETICS.com.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare
technology company on a mission to transform patient care by
expanding access to data-driven medicine globally. It is the
creator of the SOPHiA DDM™ Platform, which analyzes complex genomic
and multimodal data and generates real-time, actionable insights
for a broad global network of hospital, laboratory, and biopharma
institutions. For more information, visit SOPHiAGENETICS.com and
connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products, and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management's beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
Logo -
https://mma.prnewswire.com/media/1673202/5138255/SOPHiA_GENETICS_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/sophia-genetics-launches-comprehensive-mrd-tracking-capabilities-302362060.html
